Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 7Lung Neoplasms 7Gliosarcoma 7Glioblastoma 7Colonic Neoplasms 7Carcinoma, Hepatocellular 7Brain Neoplasms 7Esophageal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5Adenocarcinoma of Lung 5Salivary Gland Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ovarian Epithelial 4Bile Duct Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Oligodendroglioma 3Esthesioneuroblastoma, Olfactory 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Pancreatic Intraductal Neoplasms 2Mesothelioma, Malignant 2Medulloblastoma 2Hereditary leiomyomatosis and renal cell cancer 2

Interventions

cediranib 3Cisplatin 3Pemetrexed 2rilotumumab 1belinostat 1Sorafenib 1Semaxinib 1Platinum 1Gemcitabine 1Gefitinib 1Erlotinib Hydrochloride 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solitary Fibrous Tumor, Pleural × Erlotinib Hydrochloride × Clear all
NCT00039182 2013-01-24

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡